The AJMC® Product Approvals and Launches page will cover the latest FDA product approvals, as well as product launches in the United States.
FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma
Oxylanthanum Carbonate Fails to Secure FDA Approval for Hyperphosphatemia, CKD
FDA Approves At-Home Belimumab Autoinjector for Pediatric Lupus Nephritis
FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC
Breaking Down Taletrectinib’s FDA Approval: Jorge J. Nieva, MD
FDA Approves Tafasitamab for Follicular Lymphoma
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid
Garadacimab, Sebetralstat Were Both Safe to Use in Clinical Trials: Timothy Craig, DO
Combination of Garadacimab, Sebetralstat Can Help Patients With HAE: Timothy Craig, DO
Garadacimab Shuts Down Contact Pathway to Treat HAE: Timothy Craig, DO
FDA Approves Garadacimab-gxii in Hereditary Angioedema
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
Taletrectinib Approved for ROS1-Positive NSCLC
FDA Approves Clesrovimab to Prevent RSV in Infants During First Season
Retifanlimab Approval Sets New Standard of Care in Advanced Anal Cancer: Sheela Rao, MBBS, MD, FRCP
5 Key FDA Approval Dates Mark a Milestone-Filled May
Darolutamide Gains FDA Approval for Metastatic Castration-Sensitive Prostate Cancer
FDA Approval of Mepolizumab Offers New Hope for Patients With Eosinophilic COPD: Gerard Criner, MD, FACP, FACCP
FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
FDA Approves Jivi for Pediatric Patients Aged 7 to 12 Years With Hemophilia A
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer
Rozanolixizumab for gMG Approved in Japan for Self-Administration
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression
Pediatric Patients With Myasthenia Gravis Need More Treatment Options: Jonathan Strober, MD
FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC
FDA Approves Nipocalimab for Generalized Myasthenia Gravis